The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | BCMA 2+1 T-cell engager CC-93269 in patients with R/R myeloma
Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, outlines preliminary results from the first Phase I clinical study of the B-cell maturation antigen (BCMA) 2+1 T-cell engager, alnuctamab (CC-93269) in patients with relapsed or refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
